Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 14/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 12/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | AHCY | P23526 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12031062 | 1.00 | PRMT5 (0.38) | PRMT5WDR77ADKXDHAHCY | |
| SCHEMBL8140442 | 1.00 | PRMT5 (0.38) | PRMT5WDR77ADKXDHAHCY | |
| SCHEMBL20053462 | 0.90 | PRMT5 (0.39) | PRMT5WDR77ADKXDHAHCY | |
| SCHEMBL19049971 | 0.88 | PRMT5 (0.37) | PRMT5WDR77ADKXDH | |
| SCHEMBL19049923 | 0.88 | PRMT5 (0.37) | PRMT5WDR77ADKXDH | |
| SCHEMBL19050106 | 0.85 | LMNA (0.31) | — | |
| SCHEMBL23171157 | 0.85 | PRMT5 (0.36) | PRMT5WDR77ADKXDHAHCY | |
| SCHEMBL19050064 | 0.84 | PRMT5 (0.36) | PRMT5WDR77 | |
| SCHEMBL19050058 | 0.84 | XDH (0.35) | PRMT5WDR77ADKXDH | |
| SCHEMBL19050107 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-9943539-B1 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | PRMT5 1973/4885WDR77 485/4885ADK 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.